French drugmaker Ipsen (Euronext: IPN) has presented its sales performance for the year-to-date 2023.
Total sales for the nine months rose 4.6% to 2.31 billion euros ($2.44 billion), or 7.1% at constant exchange rates.
Within this, oncology product revenues down 1.3% at 1.74 billion euros (+0.8% at CER). Neurosciences sales shot up 19.9% to 489 million euros (+24.5% at CER), and rare diseases sales were unchanged at 76 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze